HK1198913A1 - Carrier-linked prodrugs having reversible carboxylic ester linkages - Google Patents
Carrier-linked prodrugs having reversible carboxylic ester linkagesInfo
- Publication number
- HK1198913A1 HK1198913A1 HK14112382.5A HK14112382A HK1198913A1 HK 1198913 A1 HK1198913 A1 HK 1198913A1 HK 14112382 A HK14112382 A HK 14112382A HK 1198913 A1 HK1198913 A1 HK 1198913A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- reversible
- carrier
- carboxylic ester
- ester linkages
- linked prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177412 | 2011-08-12 | ||
| PCT/EP2012/065748 WO2013024053A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked prodrugs having reversible carboxylic ester linkages |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198913A1 true HK1198913A1 (en) | 2015-06-19 |
Family
ID=46640699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112382.5A HK1198913A1 (en) | 2011-08-12 | 2014-12-09 | Carrier-linked prodrugs having reversible carboxylic ester linkages |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140249093A1 (de) |
| EP (2) | EP2741744A1 (de) |
| AU (1) | AU2012296955B2 (de) |
| CA (1) | CA2843506C (de) |
| HK (1) | HK1198913A1 (de) |
| WO (1) | WO2013024053A1 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013328785B2 (en) | 2012-10-11 | 2016-07-21 | Ascendis Pharma A/S | Hydrogel prodrugs |
| SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (de) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs von treprostinil |
| US20160089446A1 (en) * | 2013-04-22 | 2016-03-31 | Ascendis Pharma A/S | Modified Hydrogels |
| WO2014179295A1 (en) | 2013-04-30 | 2014-11-06 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| AU2014333954C1 (en) | 2013-10-08 | 2020-08-27 | Ascendis Pharma A/S | Protecting group comprising a purification tag |
| WO2015061720A2 (en) | 2013-10-25 | 2015-04-30 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| JP6866043B2 (ja) | 2014-11-18 | 2021-04-28 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| SG11201805026SA (en) | 2016-01-08 | 2018-07-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| EP3400020A1 (de) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp-prodrugs mit grossen trägergruppen |
| PL3400019T3 (pl) | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
| AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| EP3423103A1 (de) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases A/S | Pth-prodrugs |
| WO2018011266A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
| CN109843295B (zh) | 2016-09-29 | 2022-04-05 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
| CN117257922A (zh) | 2016-09-29 | 2023-12-22 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
| JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー／エス | 放出制御ｐｔｈ化合物の漸増用量設定 |
| EP3592393B1 (de) | 2017-03-10 | 2021-12-01 | QuiaPEG Pharmaceuticals AB | Lösbare konjugate |
| JP7216006B2 (ja) | 2017-03-22 | 2023-01-31 | ジェネンテック， インコーポレイテッド | ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法 |
| KR20210013584A (ko) | 2018-05-18 | 2021-02-04 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 개시 용량 |
| JP2021535920A (ja) | 2018-09-12 | 2021-12-23 | キアペグ ファーマシューティカルズ アクチエボラグ | 放出可能なｇｌｐ−１コンジュゲート |
| SG11202101982RA (en) | 2018-09-26 | 2021-03-30 | Ascendis Pharma As | Degradable hyaluronic acid hydrogels |
| AU2019350376A1 (en) | 2018-09-26 | 2021-03-18 | Ascendis Pharma A/S | Treatment of infections |
| CA3114329A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Novel hydrogel conjugates |
| JP2022516308A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | パターン認識受容体アゴニストのコンジュゲート |
| JP2022516314A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | 自然免疫アゴニストのための持続性局所性薬物レベル |
| US20220054477A1 (en) | 2019-01-04 | 2022-02-24 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| US20220054478A1 (en) | 2019-01-04 | 2022-02-24 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
| EP3923906A1 (de) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Trockene pharmazeutische formulierungen von cnp-konjugaten |
| US20220088149A1 (en) | 2019-02-11 | 2022-03-24 | Ascendis Pharma Bone Diseases A/S | Liquid Pharmaceutical Formulations of PTH Conjugates |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| WO2020223237A1 (en) | 2019-04-29 | 2020-11-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| CA3142439A1 (en) * | 2019-06-03 | 2020-12-10 | Duke University | Compositions and methods for bone repair and bone health |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| WO2020254611A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
| US20230102309A1 (en) | 2019-06-21 | 2023-03-30 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| WO2021144249A1 (en) | 2020-01-13 | 2021-07-22 | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism treatment |
| EP4146281A1 (de) | 2020-05-04 | 2023-03-15 | Ascendis Pharma A/S | Hydrogelbestrahlung |
| AU2021319863A1 (en) | 2020-08-05 | 2023-02-16 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
| IL301411A (en) | 2020-09-28 | 2023-05-01 | Ascendis Pharma Bone Diseases As | Improving the physical and mental condition of patients with hypoparathyroidism |
| EP4334455A1 (de) * | 2021-05-05 | 2024-03-13 | Arcturus Therapeutics, Inc. | Lipidzusammensetzungen mit peptid-lipid-konjugaten |
| AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
| WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| WO2023110727A2 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Oncology Division A/S | Novel cancer treatments with tlr7/8 agonists |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001505872A (ja) * | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
| US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| PL348487A1 (en) * | 2001-07-06 | 2003-01-13 | Pan | New esters of the acetylisalicylic acid with oligomers of the 3-hydrobutyric acid, method of their manufacture and preparations containing these esters |
| CA2843439A1 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| ITMI20030743A1 (it) * | 2003-04-11 | 2004-10-12 | Biopeg Ltd | Derivati di polietilenglicoli che rilasciano ossido nitrico. |
| CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| PL196384B1 (pl) * | 2005-01-11 | 2007-12-31 | Ct Materialow Polimerowych I W | Nowe estry niesteroidowych leków przeciwzapalnych i sposób ich wytwarzania |
| WO2006138463A2 (en) * | 2005-06-17 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| US8110559B2 (en) * | 2006-09-15 | 2012-02-07 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| WO2008118784A1 (en) * | 2007-03-23 | 2008-10-02 | Targanta Therapeutics Corp. | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
| CN101983066B (zh) * | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
| EP2596805B1 (de) | 2008-02-01 | 2021-10-27 | Ascendis Pharma A/S | Prodrug enthaltend ein Wirkstoff-Linker-Konjugat |
| JP2012525146A (ja) * | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
| BR112012002280B1 (pt) | 2009-07-31 | 2020-04-07 | Ascendis Pharma As | hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica. |
| EP2459227B1 (de) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs mit einem aromatischen Amin, die durch eine Amidbindung mit einer Trägersubstanz verbunden sind |
| EP2485767A1 (de) * | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Trägergebundene paliperidon-prodrugs |
| WO2011123830A2 (en) * | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
-
2012
- 2012-08-10 AU AU2012296955A patent/AU2012296955B2/en not_active Ceased
- 2012-08-10 EP EP12745703.4A patent/EP2741744A1/de not_active Ceased
- 2012-08-10 EP EP19200550.2A patent/EP3643306A3/de active Pending
- 2012-08-10 CA CA2843506A patent/CA2843506C/en active Active
- 2012-08-10 US US14/238,447 patent/US20140249093A1/en not_active Abandoned
- 2012-08-10 WO PCT/EP2012/065748 patent/WO2013024053A1/en active Application Filing
-
2014
- 2014-12-09 HK HK14112382.5A patent/HK1198913A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3643306A2 (de) | 2020-04-29 |
| EP2741744A1 (de) | 2014-06-18 |
| CA2843506C (en) | 2020-05-12 |
| AU2012296955B2 (en) | 2016-12-15 |
| WO2013024053A1 (en) | 2013-02-21 |
| EP3643306A3 (de) | 2020-08-26 |
| US20140249093A1 (en) | 2014-09-04 |
| CA2843506A1 (en) | 2013-02-21 |
| AU2012296955A1 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198913A1 (en) | Carrier-linked prodrugs having reversible carboxylic ester linkages | |
| HK1198359A1 (en) | Carrier-linked treprostinil prodrugs | |
| KR101881529B1 (ko) | 관점 오브젝트 선택 | |
| HK1198628A1 (en) | Polymeric hyperbranched carrier-linked prodrugs | |
| EP2797959A4 (de) | Aspartyl-trna-synthetase-fc-konjugate | |
| ZA201300837B (en) | Merchandiser | |
| GB201110558D0 (en) | Controller | |
| GB2485460B (en) | Weed control | |
| HK1200453A1 (en) | Piperidinyl naphthylacetic acids | |
| GB201119235D0 (en) | Weed control | |
| PL2366908T3 (pl) | Urządzenie uruchamiające | |
| EP2553599A4 (de) | Zeitlinie für visuelle unterhaltung | |
| GB2478013B (en) | A controller | |
| EP2686744A4 (de) | Drehbare softwareanzeige | |
| EP2734360A4 (de) | Reibungslos biegbare platte | |
| EP2548872A4 (de) | Cyclopropancarbonsäurederivat | |
| GB201211984D0 (en) | Rigless intervention | |
| EP2716274A4 (de) | Biologisch abbaubarer sarg | |
| GB201001626D0 (en) | Controller | |
| EP2761572A4 (de) | Musik auf einer video-website | |
| GB2486971B (en) | Actuator unit | |
| PL2591662T3 (pl) | Maszyna do zbioru siana | |
| GB201018912D0 (en) | Weed control | |
| GB201009499D0 (en) | A controller | |
| GB201019541D0 (en) | Nsaid prodrugs |